{"id":"W4319341650","doi":"10.1158/1078-0432.ccr-22-3298","title":"Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics","year":2023,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; Loxo Oncology; Genentech; Sierra Oncology; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Generalitat de Catalunya; Fundación Científica Asociación Española Contra el Cáncer; MacroGenics; Menarini Group; F-star Therapeutics; Banco Bilbao Vizcaya Argentaria; BeiGene; Agios Pharmaceuticals; Merck KGaA; Regeneron Pharmaceuticals; Les Laboratories Pierre Fabre; Principia Biopharma; Fundació la Marató de TV3; Fundación BBVA; Symphogen; Pfizer; Incyte; F. Hoffmann-La Roche; Ministerio de Ciencia e Innovación; European Commission; Sanofi; Centres de Recerca de Catalunya; GlaxoSmithKline; Instituto de Salud Carlos III; Amgen; Celgene; Agència de Gestió d'Ajuts Universitaris i de Recerca; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Antigen; Immunosurveillance; Immunogenicity; Cancer; Cancer research; Biology; T cell; Cancer immunotherapy; Immune system; Immunology; Immunotherapy; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001462588,0.0002317783,0.0001472825,0.0001631775,0.00009151075,0.0002247794,0.0001248012,0.000192757,0.0009399815],"category_scores_gemma":[0.0001526274,0.00006808305,0.0001623019,0.0001226681,0.0001228566,0.0001244042,0.0001593323,0.000313105,0.0002243796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001541786,"about_ca_system_score_gemma":0.00009885326,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001294189,"about_ca_topic_score_gemma":0.0001389241,"domain_scores_codex":[0.9998997,0.0000211992,0.000006443519,0.00002631385,0.00002484105,0.00002150982],"domain_scores_gemma":[0.9999084,0.0000216094,0.00003373196,0.00000887029,0.00001302331,0.00001428365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00009761582,0.00001973874,0.002949085,0.00003998359,0.000007487959,0.0000447616,0.00001120871,0.000153098,0.9950944,0.0000314982,0.00002073959,0.001530332],"study_design_scores_gemma":[0.00003000501,0.0008421203,0.05010649,0.00001296481,0.00005869074,0.001889089,0.00009740519,0.005269649,0.9394009,0.00019898,0.00208562,0.000008080732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976421,0.0003278206,0.001518818,0.00002630065,0.000002755334,0.00001527579,0.0001260566,0.000008804608,0.0003320039],"genre_scores_gemma":[0.9973058,0.0002490559,0.001745493,0.00004596581,0.000004962007,0.00001580123,0.0003825036,0.000005455866,0.000245074],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009399815,"threshold_uncertainty_score":0.003144622,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5256608444183113,"score_gpt":0.4866425423422372,"score_spread":0.0390183020760741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}